Access cutting-edge based on the study title "car-t followed by bispecific antibodies" and the context of car-t therapy, this appears to be treating: blood cancer treatment through this clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Philadelphia location
Access based on the study title "car-t followed by bispecific antibodies" and the context of car-t therapy, this appears to be treating: blood cancer specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related based on the study title "car-t followed by bispecific antibodies" and the context of car-t therapy, this appears to be treating: blood cancer treatment provided free
Check if you qualify for this based on the study title "car-t followed by bispecific antibodies" and the context of car-t therapy, this appears to be treating: blood cancer clinical trial in Philadelphia, PA
No-Cost Study Care
Local to Philadelphia
Convenient for PA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).
Sponsor: Abramson Cancer Center at Penn Medicine
Yes, this clinical trial (NCT04889716) has an active research site in Philadelphia, PA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for based on the study title "car-t followed by bispecific antibodies" and the context of car-t therapy, this appears to be treating: blood cancer treatment options in Philadelphia, PA, this clinical trial (NCT04889716) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Philadelphia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced based on the study title "car-t followed by bispecific antibodies" and the context of car-t therapy, this appears to be treating: blood cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all based on the study title "car-t followed by bispecific antibodies" and the context of car-t therapy, this appears to be treating: blood cancer clinical trials near you to find additional studies recruiting in your area.
See all leukemia clinical trials recruiting in Philadelphia — not just this study.
Browse Leukemia Trials in Philadelphia →